TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the plasma concentration-time curve (AUC) during hemodialysis for the ABT-493 study drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) during hemodialysis for the ABT-530 study drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latent toxicities graded using the Common Toxicity Criteria (CTC) version 2.0
Endpoint domain: Adverse events/effects
Primary endpoint: Grade of shivering
Endpoint domain: Adverse events/effects
Primary endpoint: Change of fasting plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in body pain index using Body Pain Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Impact of Events Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disease manifestations of uterine fibroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: extent of repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Resting State Beta Band Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sample Beta Entropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with vaccine related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with vaccine induced immune related response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recurrence-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Relative risk of presenting a febrile UTI
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of oral mucositis symptomatic events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe oral mucositis symptomatic events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Interoceptive Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MRI findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of bone and mineral metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positioning of the large and small bowel for exposure of key anatomic structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Excretion of Atypical Bile Acids in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Uptake of genetic counseling and testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reflux symptom questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pH-impedance recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of hospital admissions due to hyperkalemia, fluid overload, lower respiratory tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Doubling in HIV Pol-specific CD8 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in CMV pp65 CD8 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in HIV p24-specific IFN-gamma-secreting CD4 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in cytomegalovirus (CMV)-specific interferon (IFN)-gamma-secreting CD4 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: repeatability coefficient (RC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of CTCAE v3.0 Events 1 Month Post DEB-TACE
Endpoint domain: Adverse events/effects
Primary endpoint: Antibiotic susceptibilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC[0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-minute STS repetitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 minute STS power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Minute Walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6MWT power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Superior Mesenteric Artery Blood Flow Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Retinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Platelet count from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total effective rate of ITP patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of sleep disorders
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Correlation coefficient between OAA/S scale and Narcotrend index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in target MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in esophageal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in muscle fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain on active movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Time Bispectral Index Remains Within 10 of Target BIS of 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Performance Error (MDPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Absolute Performance Error (MDAPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Absolute Change From Baseline to Week 12 in Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline to Week 12 in Non-inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Success on the Evaluator's Global Severity Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change From Baseline on the Benton Visual Retention Test Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Change From Baseline on the California Verbal Learning Test Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in Brain Natriuretic Peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement of isovolumetric relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Compliance evaluations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Motor evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetic parameters of rabeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic parameters of rabeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety parameters of rabeprazole
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal Composite Index (NCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in survivors' use of safety strategies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in decisional conflict
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in friends' efficacy to intervene
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in friends' supportive behaviors
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Success rate in Investigator's Global Assessment (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Changes From Baseline in Total Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) at Preoperative Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) at 1 Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) at 2 Years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prescription of Isoniazid
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Local failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Muscular Strength and Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in cycloplegic objective spherical equivalent (SER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ER/PR response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time-Matched Change From Baseline in QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Th2 Cytokine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of appropriate referred patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ribavirin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Midazolam plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of postoperative confusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weaning off parenteral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Log Geometric Mean Area Under the Concentration Versus Time Curve (AUC[0-48])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean of Maximum Observed Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Elimination Half-life (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach clinical stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of hip function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response to vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Remission evaluated by DAI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in 9-hole peg test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knee extension range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of tumor cells in S and G2 phase of the cell cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progressive-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Mid-facial volumetric correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface Electrical Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percentage of Time in REM Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Offspring neurocognitive assessment at 0-3 yrs
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Offspring IQ assessment at 0-3 yrs
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time until relapse
Endpoint domain: Mortality/survival
Primary endpoint: Completion of Follow-up Appointment with PCP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total retinal blood flow changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in HIV-1 RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in genital HIV-1 RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recurrence of GB findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prescriptions of benzodiazepines and benzodiazepine-like hypnotics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants RT-PCR positive for Covid-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overweight and obesity status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BMI Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fixation time in eyes, mouth and face areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss 8 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoke alarm functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depression rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall accuracy of significant coronary artery disease (CAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of significant CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of significant CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinical Procedural Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Patients With Device Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Choroidal Perfusion Deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of motivation to adhere
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: adherence
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: reductions in HIV-1 viral loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of all treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in arterial carbon dioxide (pCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in arterial pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in arterial oxygen tension (pO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: insertion time and attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oropharyngeal leak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fiberoptic view grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carcinoma antigen 125 (CA125)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive wheal and flare responses from skin test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Continuous Glucose Monitoring Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brief Questionnaire of Smoking Urges (QSU-Brief)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attentional Bias Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in self-management ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nasal deviation angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral and intermediate nasal bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal bone length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internasal angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need to change the materials during the procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: clinical stability on day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 day admit rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Glucose-under-the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Modified AOFAS hindfoot score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in WOMAC Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Ebola Virus Glycoprotein (GP-EBOV) Antibody Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient comfort post ERCP
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cmax,ss of CKD-501, D745, D150
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau,ss of CKD-501, D745, D150
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematologic Toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Healing time with laser therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing time with protective barrier powder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline life quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CL (Clearance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Typology of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Exacerbation or Refractory TTP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Increase in High Density Lipoprotein Cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with HBV DNA below 300 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximal incremental plasma glucose level (iCmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ALP (Alkaline Phosphatase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PLP (Pyridoxal Phosphate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Number of Completed Sessions Per Participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall Survival at 12 Months (OS-12)
Endpoint domain: Mortality/survival
Primary endpoint: Early cardiovascular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mg Equivalent Morphine Used Until Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Loss of Therapeutic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of endoscopic images with clinical and histological diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes